Get the Stockscreener App
1.92
8.57%
-0.18
After Hours:
1.93
0.01
+0.52%
Ocugen Inc stock is traded at $1.92, with a volume of 17.35M.
It is down -8.57% in the last 24 hours and up +7.87% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$2.10
Open:
$2.04
24h Volume:
17.35M
Relative Volume:
2.36
Market Cap:
$629.56M
Revenue:
$4.41M
Net Income/Loss:
$-67.85M
P/E Ratio:
-8.5031
EPS:
-0.2258
Net Cash Flow:
$-57.15M
1W Performance:
-21.63%
1M Performance:
+7.87%
6M Performance:
+17.07%
1Y Performance:
+201.22%
1-Day Range:
$1.79
$2.04
1-Week Range:
$1.79
$2.56
52-Week Range:
$0.57
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.92 | 688.58M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
448.62 | 114.63B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.69 | 77.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
677.50 | 42.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.05 | 40.67B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
275.69 | 30.50B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen (NASDAQ:OCGN) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Ocugen’s Tumultuous Chapter: Earnings, Strategies, and Market Reactions - StocksToTrade
Ocugen Reports Positive Phase 2 Data for OCU410 Therapy - TipRanks
Ocugen’s Strategic Directions Amid Economic Challenges - timothysykes.com
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
Ocugen (NASDAQ: OCGN) reports strong Phase 2 OCU410 results in geographic atrophy - Stock Titan
OCU410 Phase II data show significant reduction in lesion size at 12 months - The Pharma Letter
Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls - Benzinga
Ocugen (OCGN) Shares Tumble After Phase 2 Trial Data Release - GuruFocus
Ocugen, Inc. unveils 12-month Phase 2 data for OCU410 gene therapy in GA - Traders Union
Ocugen stock falls 5% despite positive gene therapy trial data - Investing.com
Ocugen (OCGN) Reports Promising Phase 2 Results for Gene Therapy OCU410 - GuruFocus
OCGN Stock Tanks After Gene Therapy Trial Update — What Did Ocugen Announce? - Stocktwits
Ocugen stock falls on trial data for GA therapy (OCGN:NASDAQ) - Seeking Alpha
Ocugen reports 31% lesion reduction in gene therapy trial - Investing.com
Ocugen, Inc. Reports Phase 2 Results for OCU410 Showing 31% Reduction in Geographic Atrophy Lesion Growth After 12 Months - Quiver Quantitative
One-shot gene therapy cut eye-lesion growth 31% in dry AMD trial - Stock Titan
Is It Too Late To Consider Ocugen (OCGN) After Its Recent Share Price Surge - Yahoo Finance
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen a new buy at Canaccord on pipeline for retinal diseases - MSN
Ocugen Index Addition Highlights Rising Attention And Ongoing Gene Therapy Risks - Yahoo Finance
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy - Ocugen, Inc.
Ocugen (NASDAQ:OCGN) Shares Gap UpShould You Buy? - MarketBeat
Ocugen's Dose Dilemma: A Risky Bet on Gene Therapy Clarity - Bitget
Ocugen To Present Full Phase 2 ArMaDa Data Fo... - Benzinga
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT - GlobeNewswire
Ocugen, Inc.(NasdaqCM: OCGN) added to S&P Biotechnology Select Industry Index - marketscreener.com
Ocugen Secures Crucial Funding to Advance Gene Therapy Pipeline - AD HOC NEWS
Earnings Risk: Will Ocugen Inc stock recover after earnings2026 Review & Safe Entry Momentum Tips - baoquankhu1.vn
OCGN stock rallies on Wall Street optimism for clinical pipeline: Retail awaits new data - MSN
Ocugen (NASDAQ:OCGN) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Oppenheimer initiates Ocugen (OCGN) with a buy rating - MSN
OCGN gene-agnostic eye therapy could shift retinal drug development - MSN
Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating - Insider Monkey
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Faces Tough Market Challenges Amidst Financial Turmoil - StocksToTrade
Canaccord initiates coverage of Ocugen, Inc. (OCGN) with a buy rating and a $12 price target - MSN
Ocugen, Inc. Files Form 8-K Current Report with SEC – Company Details, Stock Symbol, and Compliance Information - Minichart
Ocugen receives $15 million from warrant exercise by institutional investor By Investing.com - Investing.com India
Ocugen Stock Forecast: Weighing Cash Usage Against Advanced Trial Results - Bitget
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development - The Globe and Mail
Ocugen Gains $15 Million, Extends Cash Runway to 2027 - TipRanks
Canaccord Initiates Coverage of Ocugen, Inc. (OCGN) with a Buy Rating and a $12 Price Target - Insider Monkey
Ocugen receives $15.0M from partial warrant exercise, extends cash runway into Q1 2027 - TradingView
Ocugen (NASDAQ: OCGN) raises $15M via warrant exercise, extends runway - Stock Titan
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data - Yahoo Finance
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch - Zacks Investment Research
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline - AOL.com
5 Best High Volume Penny Stocks to Buy Now - Insider Monkey
symbol__ Stock Quote Price and Forecast - CNN
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.80%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):